With the mounting tensions that the new EU MDR has put on medical device manufacturers, the ripple effects can be seen in every department at those medical device companies. By default, the regulatory affairs functions have been the worst hit and are struggling to soar up...
With the new EU MDR, companies must comply with several new requirements. Our previous blogs gave a snapshot of what has changed in the new EU MDR and how as a Medical Device manufacturer you can best deal with these changes. You can read some...
In December 2018, the U.S. Food and Drug Administration formally recognized a public database that contains information about genes, genetic variants, and their relationship to disease. This blog discusses the motivation for creating such public databases and the implications for developers of genetic tests. Upon completion...
The three-year transition period to the EU MDR does not only engage the Regulatory Affairs personnel in Medical Device companies but also the entire business leadership as well. Companies are still in the three-year transition period to comply with the EU MDR. This transition does not...
The new EU MDR is set to go into effect in May 2020. The transition to the new regulations is burdensome for some companies especially because of some newly established requirements. One such requirement is to have a Person Responsible for Regulatory Compliance [PRRC] of...
With the fast approaching Brexit date, the possibilities of Britain exiting the EU without striking a deal are very high. Prime Minister Theresa May’s exit agreement was rejected by the British Parliament on January 15, 2019, by 432 votes to 202. The deal was designed...